InnoCare Secures $3.35 Billion Licensing Agreement with Eli Lilly
Source Summary
InnoCare has entered into a licensing agreement with Eli Lilly valued at up to $3.35 billion. The deal represents a significant partnership between the two pharmaceutical companies.
Why it matters
The deal provides InnoCare with substantial capital and validates its drug candidates through partnership with a major pharmaceutical company.
